Myasthenia gravis is an autoimmune disease usually caused by autoantibodies against the muscle nicotinic acetylcholine receptor (nAChR). Current treatments are not specific, and thus often cause side effects. Here, we elaborate on our previous findings on antigen specific immunoadsorption towards scaling up the method as well as testing whole blood apheresis. The average percent of plasma or whole blood immunoadsorption was up to 79.5% ± 2.9. Moreover, neither pyrogens were co-administered nor did complement activation occur after immunoadsorption. Thus, antigen-specific apheresis of anti-AChR autoantibodies seems a safe and effective treatment for myasthenia gravis that can be scaled up for clinical testing.
Introduction
Myasthenia gravis (MG) is an autoimmune disease usually characterized by a reduced number of functional nicotinic acetylcholine receptors (nAChR), located in the postsynaptic voluntary muscle endplate membrane. The muscle AChR, a five-subunit transmembrane ligand-gated cation channel with the stoichiometry α2βγδ at immature and denervated or damaged endplate, and α2βεδ at mature normal endplate, is the target for the pathogenic anti-AChR autoantibodies (auto-Abs) in MG, whereas auto-Abs against functional proteins different than AChR may be present in myasthenic patients with no detectable circulating AChR auto-Abs (Hoch et al., 2001; Zhang et al., 2012) . Each AChR subunit consists of an N-terminal extracellular domain (ECD) containing the characteristic 13-residue long Cys-loop of the ligand-gated ion channel superfamily, four membrane spanning α-helices, a large cytoplasmic loop, and a small extracellular C-terminal tail (Karlin, 2002) . All the antigenic epitopes are located on the ECDs of the AChR while more than half of the auto-Abs are directed against the so-called main immunogenic region (MIR), a group of overlapping epitopes located on the ECD of the α1 subunit, whose central core lies between amino acids 67-76 (Tzartos et al., 1998) .
MG is clinically characterized by fluctuating weakness and fatigue. Although both T-and B-lymphocytes are involved in the autoimmune response to AChR, the specific effectors' arm of the immune response comprises solely of AChR auto-Abs that are highly disease specific and are detected in approximately 85% of patients with generalized MG (Dalakas, 2006) .
At present, the first-line symptomatic treatment for MG is the use of anticholinesterase drugs. Immunomodulatory treatment, such as thymectomy, is used for early-onset and thymoma MG, whereas immunosuppressants, such as glucocorticoids, are used for almost all patients with MG (McDaneld et al., 2010) . Plasmapheresis is mainly used as an efficient method in patients with severe MG symptoms or in myasthenic crisis, whereas administration of intravenous Ig (IVIg) is used in similar circumstances to plasmapheresis, and although it has only minor side-effects, it is also non-specific.
Plasmapheresis is a process by which a major part of the plasma of the patient, including components believed to cause or aggravate the disease, is removed from the whole blood. The cellular blood components are then combined with replacement plasma components or an inert substitute and returned to the patient. Although plasmapheresis seems an efficient therapeutic option for MG, its high cost, due to the need to replace serum proteins, and especially the concomitant removal of non pathogenic/protective Abs and/or other important molecules, are serious drawbacks (Yeh and Chiu, 2000) . 
